BRPI0414347A - associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade - Google Patents

associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade

Info

Publication number
BRPI0414347A
BRPI0414347A BRPI0414347-7A BRPI0414347A BRPI0414347A BR PI0414347 A BRPI0414347 A BR PI0414347A BR PI0414347 A BRPI0414347 A BR PI0414347A BR PI0414347 A BRPI0414347 A BR PI0414347A
Authority
BR
Brazil
Prior art keywords
prodrug
snri
ssri
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0414347-7A
Other languages
English (en)
Inventor
Stephen Peter Arneric
Cathryn Montgomery Clary
Douglas Eric Feltner
Wilma Marcia Harrison
Richard James Kavoussi
Atul Chandra Pande
Charles Price Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0414347A publication Critical patent/BRPI0414347A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"ASSOCIAçãO COMPREENDENDO UM LIGANDO DE ALFA-2-DELTA E UM SSRI E/OU SNRI PARA TRATAMENTO DE DEPRESSãO E DISTúRBIOS DA ANSIEDADE". é proporcionado um método para tratar a depressão em mamíferos, incluindo um ser humano, bem como a depressão e uma doença, distúrbio ou estado concomitante ilustrado por, mas não se restringindo a ansiedade, distúrbio do sono e distúrbio de stresse pós-traumático. O método compreende a administração ao mamífero de uma quantidade eficaz de uma associação de ingredientes ativos compreendendo a) um ligando de alfa-2delta (A2D) ou um seu pró-fármaco, ou um sal farmaceuticamente aceitável do referido ligando de A2D ou do referido pró-fármaco e, agentes ativos selecionados de; (b) um inibidor seletivo da recaptação de serotonina (SSRI) ou um seu pró-fármaco ou um sal farmaceuticamente aceitável do referido SSRI ou do referido pró-fármaco, (c) um inibidor seletivo da recaptação de noradrenalina (SNRI) ou um seu pró-fármaco ou um sal farmaceuticamente aceitável do referido SNRI ou do referido pró-fármaco e misturas de (b) e (c). é também proporcionada uma formulação farmacêutica compreendendo uma quantidade terapeuticamente eficaz de (a) um ligando de A2D ou um seu pró-fármaco, ou um sal farmaceuticamente aceitável do referido ligando de A2D ou do referido pró-fármaco e agentes ativos selecionados de; (b) um SSRI ou um seu pró-fármaco ou um sal farmaceuticamente aceitável do referido SSRI ou do referido pró-fármaco, (c) um SNRI ou um seu pró-fármaco ou um sal farmaceuticamente aceitável do referido SNRI ou do referido pró-fármaco e misturas de (b) e (c). Os ingredientes ativos preferidos para o tratamento e para a formulação farmacêutica incluem pregabalina, gabapentina, sertralina e reboxetina.
BRPI0414347-7A 2003-09-12 2004-08-30 associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade BRPI0414347A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50230403P 2003-09-12 2003-09-12
PCT/IB2004/002818 WO2005025563A1 (en) 2003-09-12 2004-08-30 Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders

Publications (1)

Publication Number Publication Date
BRPI0414347A true BRPI0414347A (pt) 2006-11-07

Family

ID=34312373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414347-7A BRPI0414347A (pt) 2003-09-12 2004-08-30 associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade

Country Status (17)

Country Link
US (1) US20050059654A1 (pt)
EP (1) EP1675582A1 (pt)
JP (1) JP2007505095A (pt)
KR (1) KR20060087560A (pt)
CN (1) CN1878546A (pt)
AR (1) AR047719A1 (pt)
AU (1) AU2004271796A1 (pt)
BR (1) BRPI0414347A (pt)
CA (1) CA2538412A1 (pt)
CO (1) CO5670327A2 (pt)
IL (1) IL173901A0 (pt)
MX (1) MXPA06002619A (pt)
NO (1) NO20061550L (pt)
RU (1) RU2006107534A (pt)
TW (1) TW200520750A (pt)
WO (1) WO2005025563A1 (pt)
ZA (1) ZA200601551B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2006038084A1 (en) * 2004-10-01 2006-04-13 Neurocure Ltd Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
CN101420947A (zh) * 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
CN101652133A (zh) * 2006-12-08 2010-02-17 克塞诺波特公司 Gaba类似物的前药用于治疗疾病的用途
WO2008129501A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of duloxetine
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
CA2706575C (en) 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
KR101129303B1 (ko) * 2011-10-19 2012-03-26 경희대학교 산학협력단 플루옥세틴을 유효성분으로 함유하는 중추신경계 질환의 예방 및 치료용 약학적 조성물
CN105579034B (zh) * 2014-09-04 2018-05-15 海思科医药集团股份有限公司 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途
SI3364975T1 (sl) 2015-10-22 2021-08-31 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Kombinacija trazodona in gabapentina za zdravljenje bolečine
US20220265579A1 (en) * 2019-05-15 2022-08-25 Vasthera Co. Ltd. Composition for preventing or treating cardio-cerebrovascular disease comprising autophagy activator as active ingredient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5559004A (en) * 1994-07-12 1996-09-24 The Regents Of The University Of California Methods for screening compounds to determine calcium leak channel inhibition activity
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
GB9801538D0 (en) * 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
YU56301A (sh) * 1999-02-23 2004-05-12 Pfizer Products Inc. Inhibitori resorpcije monoamina za tretiranje poremećaja cns
CA2367494A1 (en) * 1999-04-09 2000-10-19 Warner-Lambert Company Combinations of gaba analogs and tricyclic compounds to treat depression
AU1481701A (en) * 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
AU2001243369A1 (en) * 2000-03-14 2001-09-24 Massachusetts Institute Of Technology Composition and method to treat weight gain and obesity attributable to psychotropic drugs
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AU783516B2 (en) * 2001-04-30 2005-11-03 Warner-Lambert Company Methods, kits and compositions for using pyrrole derivatives
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
AU2003247042A1 (en) * 2002-07-10 2004-02-02 Warner-Lambert Company Llc Gastrointestinal compositions comprising gaba derivatives
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PL377286A1 (pl) * 2002-12-13 2006-01-23 Warner-Lambert Company Llc Analogi gabapentyny do włókniako-mięśniakowych i innych pokrewnych zaburzeń
JP2006511606A (ja) * 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
NZ540591A (en) * 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
EP1572187A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders

Also Published As

Publication number Publication date
IL173901A0 (en) 2006-07-05
JP2007505095A (ja) 2007-03-08
AU2004271796A1 (en) 2005-03-24
KR20060087560A (ko) 2006-08-02
EP1675582A1 (en) 2006-07-05
RU2006107534A (ru) 2007-09-20
CN1878546A (zh) 2006-12-13
AR047719A1 (es) 2006-02-15
US20050059654A1 (en) 2005-03-17
WO2005025563A1 (en) 2005-03-24
MXPA06002619A (es) 2006-06-05
NO20061550L (no) 2006-04-05
CO5670327A2 (es) 2006-08-31
TW200520750A (en) 2005-07-01
CA2538412A1 (en) 2005-03-24
ZA200601551B (en) 2007-04-25

Similar Documents

Publication Publication Date Title
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
ES2313330T3 (es) Derivados de alfa-aminoamida utiles en el tratamiento del sindrome de piernas inquietas.
CL2008003363A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual.
CA2532859A1 (en) Use of rotigotine for the treatment of depression
CO5601022A2 (es) Metodos para tratar pacientes que padecen transtornos de movimiento
TW201249425A (en) Cannabinoids for use in the treatment of neuropathic pain
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
CN113710319B (zh) 用于治疗焦虑相关病症的组合物和方法
EE05315B1 (et) Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
US7569605B2 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
JP2005512965A (ja) 不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
JP2009242360A (ja) 経口用の慢性疼痛予防または治療剤
BR0111982A (pt) Tratamento com apomorfina, de disfunção sexual induzida por droga anti depressão
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
Kiroğlu et al. Dipyrone ameliorates behavioural changes induced by unpredictable chronic mild stress: gender differences
JP2004503471A5 (pt)
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
JP2009007278A (ja) 線維筋痛症の治療薬
WO2005084330A2 (en) Compositions and methods for treating nasal congestion
BR112021026291A2 (pt) Lemborexant para tratar problemas de sono
CL2023001014A1 (es) Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.